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OBJECTIVE : To investigate immunohistochemical markers of angiogenesis and their association with
pathological prognostic features in hepatocellular carcinoma and cirrhotic liver.
METHODS: Vascular endothelial growth factor, CD105, and cyclooxygenase-2 were immunohistochemically
detected in 52 hepatocellular carcinoma tissue samples and 48 cirrhotic liver tissue samples. Semiquantitative
measurements of vascular endothelial growth factor and cyclooxygenase-2 were evaluated considering the
degree and intensity of immunostaining based on a 7-point final scoring scale. CD105 microvascular density
(MVD-CD105) was measured using automated analysis. Morphological aspects evaluated in the hepatocellular
carcinoma samples included size (p2 and 42 cm), differentiation grade, and microvascular invasion.
RESULTS: The mean vascular endothelial growth factor immunoreactivity score was slightly higher in the
hepatocellular carcinoma samples (4.83±1.35) than the cirrhotic liver (4.38±1.28) samples. There was a
significant and direct correlation between these mean scores (rs=0.645, p=0.0001). Cyclooxygenase-2 was
expressed in all the cirrhotic liver samples but was only found in 78% of the hepatocellular carcinoma samples.
The mean cyclooxygenase-2 score was higher in the cirrhotic liver samples (4.85±1.38) than the hepatocel-
lular carcinoma samples (2.58±1.68), but there was no correlation between the scores (rs=0.177, p=0.23).
The mean CD105 percentage in the hepatocellular carcinoma samples (11.2%) was lower than that in the
cirrhotic samples (16.9%). There was an inverse relationship in MVD-CD105 expression between the
hepatocellular carcinoma and cirrhotic samples (rs=-0.78, p=0.67). There were no significant associations
between vascular endothelial growth factor expression and morphological characteristics. Cyclooxygenase-2
and CD105 were associated with hepatocellular carcinoma differentiation grade (p=0.003 and p=0.05,
respectively).
CONCLUSION: Vascular endothelial growth factor, cyclooxygenase-2, and MVD-CD105 were highly expressed in
cirrhotic liver compared to hepatocellular carcinoma and might be involved in liver carcinogenesis. Additionally,
cyclooxygenase-2 and CD105 might be involved in hepatocellular carcinoma differentiation grade.
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’ INTRODUCTION
Hepatocellular carcinoma (HCC) is a peculiar neoplasm
with characteristics that differ from other tumor types, the
major difference being that it most often occurs in association
with chronic liver disease.
Gene expression studies in tumorous and surrounding
non-tumorous liver tissues have identified molecular profiles
associated with tumor differentiation, recurrence, vascular
invasion, and patient survival (1-3). Angiogenesis activation
pathways have been reported to play a role in HCC carci-
nogenesis (4).
Vascular endothelial growth factor (VEGF) is one of the
most important factors involved in tumoral angiogenesis.
VEGF is a potent endothelial cell mitogen that induces the
formation of new vessels and increases vascular permeability
(5). In addition, VEGF expression in HCC has been correla-
ted with tumor aggressiveness (capsular infiltration, vascular
invasion and intrahepatic metastasis) (6-8) and microvascu-
lar density (MVD) (9).DOI: 10.6061/clinics/2016(11)04
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Immunohistochemical evaluation of MVD using antibo-
dies against CD34, CD31, and CD105 has been performed to
evaluate tumor angiogenesis. However, CD105 is a more
specific marker for tumor angiogenesis than CD34 or CD31,
which are pan-endothelial markers (10).
Cyclooxygenase-2 (COX-2) participates in carcinogenesis
via different mechanisms, such as by promoting angiogen-
esis and cellular proliferation and inhibiting apoptosis (11).
High COX-2 expression has been demonstrated in non-HCC
tumors, including gastrointestinal cancers (12-14). In addi-
tion, COX-2 (15) (17), VEGF (6,16) and CD105 (17) are
expressed in chronic liver diseases.
Considering that VEGF, COX-2, and CD105 are involved
in tumoral angiogenesis and that HCC is a highly vascular-
ized tumor that occurs mainly in chronically diseased livers
exhibiting neoangiogenesis, we investigated immunohisto-
chemical expression patterns of VEGF, COX-2, and MVD-
CD105 in HCC and surrounding cirrhotic liver tissues.
Furthermore, we evaluated the putative association of
these markers with HCC pathological features, including
tumor size, differentiation grade, and microvascular inva-
sion status.
’ MATERIAL AND METHODS
Patients and pathology findings
We studied 52 HCC and 48 surrounding cirrhotic liver
tissue samples obtained during orthotopic liver transplanta-
tion or partial hepatectomy procedures performed in 38 male
and 14 female adult patients with cirrhosis (aged 18–69
years). Forty-three patients had hepatitis C virus infection in
isolation or in association with other etiologies. Twenty-six
tumors were p2 cm in diameter, and 26 were 42 cm in
diameter. According to grading, 40 of the 52 HCC tumors
were well differentiated (grade I and II), 7 were moderately
differentiated (grade III), and 5 were poorly differentiated
(grade IV). In cases with more than one histological grade,
the highest grade was considered. Microvascular invasion
was present in 23 (44.2%) tumors.
This study was approved by the local ethics committee of
our institution (No 163/11)
Immunohistochemistry
Paraffin-embedded tissues were sectioned. The sections
(5 mm) were deparaffinized in xylene, dehydrated and
rehydrated in ethanol, and subjected to steamer antigen
retrieval. The sections were then processed using a Novocas-
tra Novolink polymer detection system (Leica Biosystems
Newcastle Ltd, UK) with the following primary antibodies:
mouse anti-human VEGF C-1 (sc-7269, 1:6000; Santa Cruz
Biotechnology Inc, USA), mouse anti-human CD105 (Endo-
glin) (clone 4G11, 1:60; Leica Biosystems Newcastle Ltd, UK),
and rabbit anti-human COX-2 (clone SP21,SPB-M3212, 1:500;
Spring Bioscience, USA). Negative controls lacked the pri-
mary antibody and were processed simultaneously.
Evaluation of immunohistochemical staining
VEGF and COX-2 immunostaining was scored semiquan-
titatively according to modification of a previous method
(18). Briefly, positive immunostaining was assessed in tumor
cells for the HCC samples or hepatocytes for the cirrhotic
tissues. Staining intensity was scored as 0, negative; 1, weak;
2, moderate; or 3, strong. The degree of staining was scored
based on the percentage of positive cells as follows:
0, 0–4.9%; 1, 5–25%; 2, 26–50%; 3, 51–75%; and 4, 76–100%.
When there was any doubt in the score to be assigned, the
highest score was chosen. The sum of the intensity and the
degree of the staining scores was used to produce a final
overall score as follows: 0–1, negative; 2–3, weak; 4–5,
moderate; and 6–7, strong. Lastly, the final mean scores were
evaluated for all tissues.
CD105-stained tissues were evaluated using computer-
based quantitative analysis to assess MVD. For the analyses,
3 microscope fields showing the highest staining intensity
(hot spots), such as blood vessels or endothelial cells, were
examined using an Olympus microscope, model BX-40.
All images were captured using an Olympus digital 3.3-
megapixel camera attached to the microscope. The images
were analyzed using the ‘‘color function’’ and area/density
measurement function in Imagelabs software. The MVD-
CD105 percentages were calculated over a fixed area of 216 mm
for each field. The average of the 3 fields was recorded as the
mean MVD score.
Statistical analysis
Fisher’s exact test or the w2 test was used to compare
categorical variables. The Mann-Whitney test or Spearman’s
rank (rs) correlation coefficient was used to compare con-
tinuous variables. Quantitative data are presented as the
mean±standard deviation (SD). Statistical analyses were
performed using SASs System software, version 6.11 (SAS
Institute, Inc., Cary, North Carolina), and po0.05 was con-
sidered statistically significant. The statistical methods used
in this study were reviewed by a biomedical statistician from
the Division of Biostatistics at Clementino Fraga Filho
Hospital.
’ RESULTS
VEGF, COX-2, and MVD-CD105 expression in HCC
samples and surrounding cirrhotic liver tissues
Diffuse cytoplasmic VEGF expression was detected in all
HCC and cirrhotic liver tissue samples. The mean VEGF
score was slightly higher in the HCC tissues (4.83±1.35)
compared with the cirrhotic tissues (4.38±1.28). There was a
significant and direct association between VEGF expression
in the HCC and cirrhotic tissues (rs=0.645, p=0.0001). COX-2
was expressed in all the cirrhotic liver samples but only in
78% of the HCC samples. The mean COX-2 score was higher
in the cirrhotic tissues (4.85±1.38) compared with the HCC
tissues (2.58±1.68), but there was no association between the
two (rs=0.177, p=0.23). The mean MVD-CD105 values were
lower in all HCC samples (11.2%) compared to cirrhotic
tissues (16.9%). Although there was no significant correlation
in MVD-CD105 percentages between the HCC and cirrhotic
tissues, an inverse relationship was apparent (rs=-0.78,
p=0.67). Examples of immunohistochemical staining in the
HCC and cirrhotic tissues are shown in Figure 1.
Correlation of VEGF, COX-2, and MVD-CD105 with
pathological features
In the HCC cases, cytoplasmic VEGF expression in tumor
cells was mostly moderate or strong (48.32% or 36.53%,
respectively). Although expression intensity did not signifi-
cantly differ in relation to tumor size (p=0.37), a moderate
expression pattern predominated in smaller tumors (o2 cm).
There was no association between VEGF expression and
HCC differentiation grade or microvascular invasion status,
640
HCC and cirrhotic liver angiogenic biomarkers
Ribeiro OD et al.
CLINICS 2016;71(11):639-643
although moderate-intensity staining predominated in well-
differentiated HCC (Table 1). COX-2 expression was signifi-
cantly associated with HCC differentiation grade (p=0.003),
but not with size or microvascular invasion status (Table 2).
Likewise, the mean MVD-CD105 values were not associated
with microvascular invasion status or tumor size in the HCC
tissues, although the mean MVD-CD105 expression tended to
be higher in smaller tumors (p2 cm). However, MVD-CD105
expression was significantly higher in well-differentiated HCC
tissues compared with poorly and moderately differentiated
tissues (p=0.05) (Table 3). There were no correlations between
the mean VEGF, COX-2, or MVD-105 scores. However, inverse
relationships were noted between the MVD-105 and VEGF
scores (rs=-0.13, p=0.33) and the MVD-105 and COX-2 scores
(rs=-0.15, p=0.29).
’ DISCUSSION
VEGF acts as a key mediator of tumoral angiogenesis
by increasing vascular permeability and promoting endothe-
lial proliferation and migration (19). In the liver carcinogen-
esis, the VEGF expression increases gradually from its early
stages (20). VEGF expression has been associated with
patient prognosis in terms of overall survival and recurrence
(21), including after liver transplantation when observed in
adjacent cirrhotic tissue (22).
Figure 1 - Immunohistochemical staining in HCC and cirrhotic tissues. Immunohistochemical staining in HCC samples: VEGF (A),
COX-2 (C), and CD-105 (E). Immunohistochemical staining in cirrhotic liver samples: VEGF (B), * refers to the area of expression of COX-2 (D),
and CD-105 (F).
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Our data showed that mean VEGF expression was slightly
higher in HCC tissues compared with surrounding cirrhotic
tissues, and there was a positive correlation between them.
This suggested a close relationship between VEGF expres-
sion and carcinogenesis, which was congruent with previous
observations (23) and reinforces the importance of VEGF in
HCC. Conversely, other studies have reported the predomi-
nance of VEGF in non-tumorous cirrhotic tissue (6,24), but
not in cirrhotic nodules distant from HCC (25). It is possible
that we observed higher VEGF scores in HCC because we
evaluated smaller tumors (p2 cm) than those examined in
other studies (5 cm). In the present study, all HCC and
surrounding cirrhotic tissues expressed VEGF, which is in
agreement with the findings of Imura et al. (26), who
observed VEGF expression in all HCC tissues. In contrast, in
another study, VEGF positivity was reported in 66.7% of HCC
samples and 79.4% of cirrhotic tissues (6). Disagreements
between studies using immunohistochemical profiling might
arise because of the different methods employed to score
staining. However, in accordance with the same study (6), we
did not observe any significant associations between VEGF
expression and differentiation grade, microvascular inva-
sion status, or tumor size. This might suggest that VEGF-
stimulated angiogenesis does not change significantly during
HCC progression.
In HCC, vascularization can result in the development of
new vessels by neoangiogenesis or from the preexisting
sinusoidal network by angiogenesis (27). MVD, assessed by
CD105 immunostaining, has been suggested as a quantita-
tive measure of tumoral angiogenesis and has been reported
as a prognostic indicator of outcome in malignant tumors,
including HCC (7). In the present study, MVD-CD105
expression was slightly higher in smaller tumors, although
it was not significantly different compared to that in larger
tumors (42 cm). Similarly, MVD-CD105 expression was
not associated with microvascular invasion status, but it
was associated with well-differentiated HCC. Additionally,
MVD-CD105 expression tended to decrease as grade in-
creased. Ho et al. (28) found a correlation between lowMVD-
CD105 expression and a more aggressive tumor type, as
indicated by a large size and microvascular invasion. It is
possible that the lack of association between MVD-CD105
expression and microvascular invasion in the present study
resulted from the smaller average size of the advanced
lesions that were examined (4.8 cm); in contrast to our
current work, Ho et al. compared tumors that werep5 cm in
diameter with those 45 cm in diameter. Such findings in
combination with our previous observations (29) suggest
that MVD-CD105 expression decreases during carcinogen-
esis and tumor progression.
COX-2 overexpression has been documented in patients
with HCC with concomitant hepatitis virus infection (14).
Immunohistochemical staining revealed COX-2 expression
in the majority of HCC tissues and all cirrhotic tissues eval-
uated in the present study, which was concordant with
previous studies (15) (17). Moreover, previous studies have
indicated that COX-2 RNA expression is higher in adjacent
liver tissues than in HCC tissues (30). In contrast, other
reports have found 100% of HCC samples showing COX-2
positivity (31,32). Hepatitis C virus infection can promote
COX-2 expression (33), which might explain why all the non-
tumorous tissues in the present study were COX-2-positive.
We found that COX-2 expression was associated with HCC
differentiation grade, but not with microvascular invasion
status or tumor size. COX-2 expression was higher in well-
differentiated HCC, suggesting that it may be involved in
the early stages of carcinogenesis (31,32). Cervello et al. (32)
suggested that COX-2 overexpression in tumor progression
might cause growth disadvantages in certain cells. Regard-
ing tumor size, Koga et al. (31) observed a predominance of
COX-2 in small HCC tumors compared with large tumors.
Epigenetic studies have implied that reduced COX-2 expres-
sion is associated with poor prognosis in patients with
HCC (30).
In conclusion, this study shows that VEGF, COX-2, and
MVD-CD105 expression were higher in cirrhotic liver tissues
compared with HCC tissues, which suggests that these
proteins play important roles in liver carcinogenesis. In
Table 1 - VEGF expression patterns according to morphological
features.
VEGF expression (%)
Variables n N Weak Mod Strong p
Size 0.37
p2.0 cm 26 - 15.4 57.7 26.9
42.0 cm 26 - 15.4 38.5 46.1
Differentiation 0.91
Grade I/II 40 - 15.0 50.0 35.0
Grade III/IV 12 - 16.7 41.7 41.6
MI invasion 0.53
Present 23 - 17.4 39.1 43.5
Absent 29 - 13.8 55.2 31.0
N – negative; Mod – moderate; MI – microvascular
Table 2 - Cox-2 expression patterns according to morphological
features.
COX-2 expression (%)
Variables n N Weak Mod Strong p
Size 0.12
p2.0 cm 26 15.4 57.6 23.1 3.9
42.0 cm 26 26.9 30.8 42.3 -
Differentiation 0.003
Grade I/II 40 10.0 52.5 35.0 2.5
Grade III/IV 12 58.3 16.7 25.0 -
MI invasion 0.84
Present 23 26.1 39.1 34.8 -
Absent 29 17.2 48.3 31.0 3.5
N – negative; Mod – moderate; MI – microvascular
Table 3 - Microvascular density of CD105 according to
morphological features.
MDV-CD105
Variables n Average SD p
Size 0.1
p2.0 cm 26 12.5 5.2
42.0 cm 26 9.92 4.43
Differentiation 0.05
Grade I/II 40 11.9 5.0
Grade III/IV 12 8.87 4.49
MI invasion 0.12
Present 23 9.8 3.9
Absent 29 12.31 5.48
N – negative; SD – standard deviation; MI – microvascular;
MDV – microvascular density
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addition, both COX-2 and MVD-CD105 expression appeared
to play roles in HCC differentiation.
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